{"id":530969,"date":"2025-03-15T19:05:35","date_gmt":"2025-03-15T16:05:35","guid":{"rendered":"https:\/\/analyse.optim.biz\/?p=530969"},"modified":"2025-03-15T19:05:35","modified_gmt":"2025-03-15T16:05:35","slug":"un-medicament-oral-pentru-contraceptia-masculina-rezultate-pozitive-dupa-primele-teste-la-om","status":"publish","type":"post","link":"https:\/\/analyse.optim.biz\/?p=530969","title":{"rendered":"Un medicament oral pentru contracep\u0163ia masculin\u0103, rezultate pozitive dup\u0103 primele teste la om"},"content":{"rendered":"<div class=\"post-content\">\n<p>O pilul\u0103 contraceptiv\u0103 experimental\u0103 f\u0103r\u0103 hormoni pentru b\u0103rba\u0163i pare s\u0103 fie sigur\u0103 pe baza primelor studii pe oameni \u015fi a prevenit cu succes produc\u0163ia de spermatozoizi \u00een studiile pe mamifere, potrivit companiei care o dezvolt\u0103, transmite News.ro.<\/p>\n<p>Medicamentul, YCT-529, func\u0163ioneaz\u0103 prin interferarea cu semnalizarea vitaminei A necesar\u0103 pentru producerea spermei. Fertilitatea revine atunci c\u00e2nd tratamentul este \u00eentrerupt.<\/p>\n<p>\u00centr-un studiu \u00een stadiu incipient, pilula contraceptiv\u0103 a fost bine tolerat\u0103 la o varietate de doze, f\u0103r\u0103 probleme de siguran\u0163\u0103 \u015fi f\u0103r\u0103 evenimente adverse grave, a declarat Akash Bakshi, CEO YourChoice Therapeutics.<\/p>\n<p>Un studiu de 28 de zile pe 50 de b\u0103rba\u0163i cu v\u00e2rste cuprinse \u00eentre 28 \u015fi 70 de ani este acum \u00een curs de desf\u0103\u015furare, iar un studiu de etap\u0103 intermediar\u0103 de 90 de zile este a\u015fteptat s\u0103 \u00eenceap\u0103 \u00een al doilea trimestru al acestui an, informeaz\u0103 Reuters.<\/p>\n<p>La \u015foareci \u015fi la primate, pilula a provocat infertilitate \u00een dou\u0103 s\u0103pt\u0103m\u00e2ni, iar animalele \u015fi-au rec\u0103p\u0103tat fertilitatea dup\u0103 \u00eentreruperea tratamentului, f\u0103r\u0103 efecte adverse, au raportat cercet\u0103torii joi \u00een revista\u00a0<a href=\"https:\/\/newslink.reuters.com\/click\/38998526.3711\/aHR0cHM6Ly93d3cubmF0dXJlLmNvbS9hcnRpY2xlcy9zNDM4NTYtMDI1LTAwNzUyLTc_dXRtX3NvdXJjZT1TYWlsdGhydSZ1dG1fbWVkaXVtPU5ld3NsZXR0ZXImdXRtX2NhbXBhaWduPUhlYWx0aC1Sb3VuZHMmdXRtX3Rlcm09MDMxMzI1JmxjdGc9NjIyZWZmMzhkMWVhYjcxZWE3NGM3NDdi\/622eff38d1eab71ea74c747bBb6ee82b8\" target=\"_blank\">Communications Medicine<\/a> .<\/p>\n<p>Un contraceptiv reversibil pentru b\u0103rba\u0163i, care se administreaz\u0103 pe cale oral\u0103 \u201ear reprezenta scenariul optim din perspectiva u\u015furin\u0163ei administr\u0103rii \u015fi aderen\u0163ei pacientului la tratament\u201d, au notat cercet\u0103torii.<\/p>\n<div id=\"vi-wrap\">\n<h4>Urm\u0103re\u0219te mai jos produc\u021biile video ale G4Media:<\/h4>\n<\/div>\n<\/div>\n<p> Source URL: https:\/\/www.g4media.ro\/un-medicament-oral-pentru-contraceptia-masculina-rezultate-pozitive-dupa-primele-teste-la-om.html<\/p>\n","protected":false},"excerpt":{"rendered":"<p>O pilul\u0103 contraceptiv\u0103 experimental\u0103 f\u0103r\u0103 hormoni pentru b\u0103rba\u0163i pare s\u0103 fie sigur\u0103 pe baza primelor studii pe oameni \u015fi a prevenit cu succes produc\u0163ia de spermatozoizi \u00een studiile pe mamifere, potrivit companiei care o dezvolt\u0103, transmite News.ro. Medicamentul, YCT-529, func\u0163ioneaz\u0103 prin interferarea cu semnalizarea vitaminei A necesar\u0103 pentru producerea spermei. Fertilitatea revine atunci c\u00e2nd tratamentul [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":530970,"comment_status":"open","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2],"tags":[24],"class_list":["post-530969","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-politics","tag-g4media"],"_links":{"self":[{"href":"https:\/\/analyse.optim.biz\/index.php?rest_route=\/wp\/v2\/posts\/530969","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/analyse.optim.biz\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/analyse.optim.biz\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/analyse.optim.biz\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/analyse.optim.biz\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=530969"}],"version-history":[{"count":0,"href":"https:\/\/analyse.optim.biz\/index.php?rest_route=\/wp\/v2\/posts\/530969\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/analyse.optim.biz\/index.php?rest_route=\/wp\/v2\/media\/530970"}],"wp:attachment":[{"href":"https:\/\/analyse.optim.biz\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=530969"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/analyse.optim.biz\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=530969"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/analyse.optim.biz\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=530969"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}